Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 5.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosin II 4.25% in Dextrose 25% provides essential amino acids and dextrose for parenteral nutrition. Amino acids serve as building blocks for protein synthesis, while dextrose supplies a source of calories to prevent catabolism. The combination aims to maintain nitrogen balance and support metabolic functions.
Travasol 5.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting metabolic functions in parenteral nutrition.
Administer as a continuous intravenous infusion. Typical adult dose: 1.0-1.5 g amino acids/kg/day (equivalent to approximately 23-35 mL/kg/day of AMINOSYN II 4.25% in DEXTROSE 25%) via central venous line. Adjust based on metabolic needs and tolerance.
500 mL of 5.5% amino acid solution intravenously over 2-4 hours daily, titrated to nitrogen balance and metabolic tolerance.
None Documented
None Documented
Amino acids: 0.5-2 hours; dextrose: 1-4 hours in non-diabetic patients; context: reflects rapid uptake and metabolism
Not applicable as individual amino acids have variable half-lives (minutes to hours). TRAVASOL is a mixture; the clinical context is continuous infusion to maintain plasma levels.
Renal: >90% as amino acids and metabolites; biliary/fecal: minimal (<2%)
Amino acids in TRAVASOL 5.5% are metabolized and nitrogen waste is excreted primarily via renal elimination (as urea, >90% of nitrogen). Fecal elimination is negligible (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution